In addition, overexpression of HER2 in breast cancer is associated with disease recurrence and poor prognosis andHER2+ cells respond to monoclonal antibody trastuzumab and this has improved the prognosis significantly. The gene discussed is ERBB2; the disease is breast carcinoma.